Literature DB >> 31251426

Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.

Christina S Lee1, Robert Rosales1,2, Michael D Stein3, Mariana Nicholls1, Bridget M O'Connor1, Vanessa Loukas Ryan4, Elizabeth A Davis4,5.   

Abstract

BACKGROUND AND OBJECTIVES: Patients are at risk of dropout while waiting for buprenorphine treatment. Study goals are to compare 3-month retention in two different methods to buprenorphine initiation among persons with opioid use disorder.
METHODS: We compared 3-month treatment retention rates of low-barrier buprenorphine initiation (i.e., rapid induction) (n =58) or a traditional method of buprenorphine initiation ( n = 45) for persons with opioid use disorder seen at an urban community health center.
RESULTS: Logistic regression revealed that low-barrier initiation had 11.11 greater odds of retention compared with traditional methods (p <0.001). Latinx patients benefited more than non-Latinx patients (OR = 14.79, p =.039). DISCUSSION AND
CONCLUSIONS: All patients were more likely to be retained using low-barrier initiation. A significantly larger effect on retention among Latinx patients was observed. SCIENTIFIC SIGNIFICANCE: Rapid buprenorphine initiation increases treatment retention which improves treatment outcomes for persons with opioid use disorder. Study findings support a less restrictive services model that is even more effective for Latinx patients. (Am J Addict 2019;28:409-412).
© 2019 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31251426      PMCID: PMC6706284          DOI: 10.1111/ajad.12925

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  12 in total

Review 1.  Clinical practice. Office-based treatment of opioid-dependent patients.

Authors:  David A Fiellin; Patrick G O'Connor
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

2.  Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013.

Authors:  Brendan Saloner; Shankar Karthikeyan
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

3.  Buprenorphine retention in primary care.

Authors:  Michael D Stein; Patricia Cioe; Peter D Friedmann
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

4.  Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness.

Authors:  Daryle E A Deering; Janie Sheridan; J Douglas Sellman; Simon J Adamson; Sheridan Pooley; Rhonda Robertson; Charles Henderson
Journal:  Addict Behav       Date:  2011-01-13       Impact factor: 3.913

Review 5.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

6.  Linking patients with buprenorphine treatment in primary care: Predictors of engagement.

Authors:  Claire B Simon; Judith I Tsui; Joseph O Merrill; Addy Adwell; Elsa Tamru; Jared W Klein
Journal:  Drug Alcohol Depend       Date:  2017-10-10       Impact factor: 4.492

7.  Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.

Authors:  Christina S Lee; Jane M Liebschutz; Bradley J Anderson; Michael D Stein
Journal:  Am J Addict       Date:  2017-03-21

8.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

9.  Does Integrated Behavioral Health Care Reduce Mental Health Disparities for Latinos? Initial Findings.

Authors:  Ana J Bridges; Arthur R Andrews; Bianca T Villalobos; Freddie A Pastrana; Timothy A Cavell; Debbie Gomez
Journal:  J Lat Psychol       Date:  2014-02

Review 10.  Opioid substitution therapy: Lowering the treatment thresholds.

Authors:  Georgios Kourounis; Brian David Wensley Richards; Evdokia Kyprianou; Eva Symeonidou; Minerva-Melpomeni Malliori; Lampros Samartzis
Journal:  Drug Alcohol Depend       Date:  2015-12-30       Impact factor: 4.492

View more
  5 in total

1.  Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.

Authors:  Andrea Jakubowski; Tiffany Lu; Frank DiRenno; Benjamin Jadow; Angela Giovanniello; Shadi Nahvi; Chinazo Cunningham; Aaron Fox
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice.

Authors:  Shashi N Kapadia; Judith L Griffin; Justine Waldman; Nicolas R Ziebarth; Bruce R Schackman; Czarina N Behrends
Journal:  Subst Use Misuse       Date:  2021-12-10       Impact factor: 2.164

3.  Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge.

Authors:  Payel J Roy; Ryan Price; Sugy Choi; Zoe M Weinstein; Edward Bernstein; Chinazo O Cunningham; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-04-20       Impact factor: 4.852

4.  The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial.

Authors:  Lauren K Whiteside; Ly Huynh; Sophie Morse; Jane Hall; William Meurer; Caleb J Banta-Green; Hannah Scheuer; Rebecca Cunningham; Mark McGovern; Douglas F Zatzick
Journal:  J Subst Abuse Treat       Date:  2021-11-24

5.  Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.

Authors:  Ellis Jaewon Yeo; Hannah Kralles; David Sternberg; Dana McCullough; Ajetha Nadanasabesan; Richard Mayo; Hana Akselrod; Jillian Catalanotti
Journal:  Harm Reduct J       Date:  2021-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.